In the abstract titled “Analgesia during long-term lubiprostone therapy in patients with opioid-induced constipation and chronic, non-cancer pain: results from a phase 3, open-label clinical trial” (Joswick et al, J Pain 14:S79, 2013) the following correction should be made: During the study, 24.6% of patients reported a treatment-related adverse event (AE), most commonly nausea and diarrhea (5.0% and 4.6%, respectively). No drug-related serious AEs were reported. Five (1.1%) and 5 (1.1%) patients withdrew because of nausea and diarrhea, respectively; 2 cases of nausea and 2 cases of diarrhea were severe. Reliance on rescue medication decreased from 33.0% to 18.6% of patients from months 1 to 9.
Article info
Identification
Copyright
© 2013 Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Analgesia during long-term lubiprostone therapy in patients with opioid-induced constipation and chronic, non-cancer pain: results from a phase 3, open-label clinical trialThe Journal of PainVol. 14Issue 4
- PreviewOpioid use is usually associated with opioid-induced constipation (OIC). The primary objective of this 9-month extension study was to evaluate the long-term safety of open-label lubiprostone 24 mcg, a locally acting chloride channel (ClC-2) activator, twice daily in adults (N=439) with chronic non-cancer pain and OIC. Consistent treatment with a full-agonist opioid was required during the study. OIC was defined as <3 spontaneous bowel movements (SBMs)/week, of which ≥25% were hard to very hard consistency, incompletely evacuated, and/or associated with moderate or worse straining, during the 2-week baseline period.
- Full-Text
- Preview
